APA (7th ed.) Citation

SC, R., H, L., AF, H., M, L., S, A., K, D., . . . AM, E. (2025). Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43(27), 2968. https://doi.org/10.1200/JCO-25-00204

Chicago Style (17th ed.) Citation

SC, Rutherford, et al. "Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 43, no. 27 (2025): 2968. https://doi.org/10.1200/JCO-25-00204.

MLA (9th ed.) Citation

SC, Rutherford, et al. "Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 43, no. 27, 2025, p. 2968, https://doi.org/10.1200/JCO-25-00204.